A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis
- Disease/Condition
- Psoriasis
- Drug/Device/Intervention
- SAR441566
- Study type
- Interventional
- Intervention type
- drug
- Primary sponsor
- Sanofi
- Location
- Indianapolis,London,Waterloo, Canada,United States of America
- Phase
- Phase 2
- Start date
- Oct 26, 2023
- End date
- Apr 24, 2025
- Enrollment
- 207 participants
Proportion of participants with a 75% or greater PASI score (Psoriasis Area and Severity Index score) improvement (reduction) from baseline (PASI75) at week 12
This is a Phase 2, international, multicenter, randomized, double-blind, placebo-controlled,
 dose-ranging, 12-week study. It is designed to assess the therapeutic dose, efficacy, and
 safety of treatment with SAR441566 in male and female adults with moderate to severe plaque
 psoriasis. Study details include a screening period (4 weeks and not less than 11 days before
 Day 1), a treatment period (12 weeks ± 3 days) and a post-treatment period (safety follow-up)
 (2 weeks ± 3 days). The total number of study visits will be 7.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06073119
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06073119 through Pure Global AI's free database. This Phase 2 trial is sponsored by Sanofi and is currently Recruiting. The study focuses on Psoriasis. Target enrollment is 207 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.